Gliogene: Brain Tumor Linkage Study

Status unconfirmed

Conditions studied: Brain Tumor, Glioma

In brief

The goal of this research study is to investigate the role of genes that may point to a higher risk of developing a glioma. Researchers will use new gene mapping techniques to study how high-risk factors are passed on through a family's genes and increase the risk of developing gliomas. Objectives: We propose an international multi-center, multidisciplinary study consortium, GLIOGENE, to identify susceptibility genes in high-risk familial brain tumor pedigrees using the most sophisticated genetic analysis methods available. To address our hypothesis, we propose the following specific aims: Aim 1: Establish a cohort of 400 high-risk pedigrees for genetic linkage analysis. To date, we have identified and collected biologic samples from 20 high-risk families that have met our criteria of 2 or more relatives diagnosed with a brain tumor. From the 15 centers in the United States and Europe, we will screen and obtain epidemiologic data from approximately 17,080 gliomas cases to identify a target of 400 families for genetic analysis. We will establish a cohort of the first and second-degree relatives from these glioma cases to obtain new knowledge about how cancer aggregates in glioma families. We will also acquire biospecimens (blood and tumor tissue), and risk factor data from relevant family members. Aim 2: Identify candidate regions linked to familial brain tumors. To strengthen evidence of linkage to regions found in our preliminary analysis and to identify additional regions linked to brain tumors, we will genotype informative glioma pedigrees identified in aim 1 using Affymetrix 10K GeneChip with markers spaced throughout the genome, and conduct a genome-wide multipoint linkage scan with these markers. Aim 3: Fine map the regions established in Aim 2 by genotyping selected SNPs from genome databases. We will attempt to further refine the regions identified in Aim 2 to less than 1cM by using approximately 1,500 - 2,000 carefully selected SNPs. The prioritization of regions will be based on a combination of the strength of evidence for linkage from families of various ethnic backgrounds and the presence of obvious candidate genes.

Key facts

Study ID

NCT00418899

Run by

M.D. Anderson Cancer Center

People needed

17080

Starts

2004-02-12

Expected to finish

2022-09-01

Last updated by the study team

2020-12-31

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• An affected or unaffected member of a family that has two or more reported gliomas (ICD9 codes 191.0-191.9) in the family.

You may not qualify if…

• N/A

Where it is running

• University of California Medical Center, San Francisco — San Francisco, California, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• University of Illinois Medical Center, Chicago — Chicago, Illinois, United States
• Evanston NW Healthcare — Evanston, Illinois, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Baylor College of Medicine — Houston, Texas, United States
• Texas Children's Hospital — Houston, Texas, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Institute of Cancer Epidemiology — Copenhagen, Denmark
• Tampere University Hospital — Tampere, Finland
• The Danek Gertner Institute — Tel Litwinsky, Israel
• Umeå University Hospital — Umeå, Sweden
• Institute of Cancer Research — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.